CENTESSA PHARMACEUTICALS (260) — Cash Flow-to-Debt Ratio
CENTESSA PHARMACEUTICALS (260) has a Cash Flow-to-Debt Ratio of -0.47x as of March 2026, meaning its operating cash flow of €-72.22 Million could theoretically repay 0% of its total liabilities (€154.41 Million) in one year. For the full cash flow conversion analysis, see cash efficiency ratio of CENTESSA PHARMACEUTICALS.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CENTESSA PHARMACEUTICALS Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for CENTESSA PHARMACEUTICALS across 4 annual periods. See financial flexibility index of CENTESSA PHARMACEUTICALS to measure the company's free cash flow as a share of total liabilities.
Annual Cash Flow-to-Debt Ratio for CENTESSA PHARMACEUTICALS (2022–2025)
Year-by-year debt coverage analysis for CENTESSA PHARMACEUTICALS. See CENTESSA PHARMACEUTICALS (260) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.21x | €-193.82 Million | €160.63 Million | ▼ -48.9% |
| 2024 | -0.81x | €-142.06 Million | €175.25 Million | ▲ +37.3% |
| 2023 | -1.29x | €-160.34 Million | €124.00 Million | ▲ +30.3% |
| 2022 | -1.85x | €-200.55 Million | €108.14 Million | — |